Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CCMNASDAQ:OPGNNASDAQ:PIIINASDAQ:PMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCCMConcord Medical Services$7.64+6.4%$4.77$3.80▼$26.70$33.17M-0.8424,342 shs34,345 shsOPGNOpGen$4.99+0.2%$3.45$0.53▼$5.30$41.70M-1.7110,777 shs1,084 shsPIIIP3 Health Partners$8.51-1.3%$8.84$7.00▼$39.50$61.08M0.9420,574 shs16,281 shsPMDPsychemedics$2.67$2.52$1.63▼$3.25$16.31MN/A27,470 shs113,627 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCCMConcord Medical Services+2.36%-12.87%+69.33%+52.90%+12.47%OPGNOpGen-3.30%0.00%+42.69%+298.40%+1.30%PIIIP3 Health Partners-1.82%-4.12%+1.41%-15.16%-75.84%PMDPsychemedics0.00%0.00%0.00%0.00%+5.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCCMConcord Medical Services0.5932 of 5 stars0.03.00.00.01.01.70.6OPGNOpGenN/AN/AN/AN/AN/AN/AN/AN/APIIIP3 Health Partners1.8096 of 5 stars3.34.00.00.00.60.80.6PMDPsychemedicsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCCMConcord Medical Services 0.00N/AN/AN/AOPGNOpGen 0.00N/AN/AN/APIIIP3 Health Partners 2.50Moderate Buy$16.2591.06% UpsidePMDPsychemedics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest PMD, PIII, OPGN, and CCM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/21/2025PIIIP3 Health PartnersLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$50.00 ➝ $20.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCCMConcord Medical Services$383.96M0.09N/AN/A$56.67 per share0.13OPGNOpGen$2.67M15.60N/AN/A($11.55) per share-0.43PIIIP3 Health Partners$1.50B0.04$3.67 per share2.32$0.45 per share18.90PMDPsychemedics$22.10M0.74N/AN/A$1.15 per share2.32Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCCMConcord Medical Services-$41.93MN/A0.00∞N/AN/AN/AN/AN/AOPGNOpGen-$32.67MN/A0.00∞N/A-1,140.36%N/A-287.58%6/2/2025 (Estimated)PIIIP3 Health Partners-$57.77M-$49.00N/AN/AN/A-6.95%-71.31%-11.93%5/14/2025 (Estimated)PMDPsychemedics-$4.15M-$0.51N/A∞N/A-14.59%-49.05%-27.26%N/ALatest PMD, PIII, OPGN, and CCM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025PIIIP3 Health Partners-$5.00N/AN/AN/A$362.09 millionN/A3/27/2025Q4 2024PIIIP3 Health Partners-$8.50-$16.00-$7.50-$0.36$378.88 million$370.69 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCCMConcord Medical ServicesN/AN/AN/AN/AN/AOPGNOpGenN/AN/AN/AN/AN/APIIIP3 Health PartnersN/AN/AN/AN/AN/APMDPsychemedicsN/AN/A-8.04%N/A1 YearsCompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCCMConcord Medical Services1.150.470.46OPGNOpGenN/A5.455.45PIIIP3 Health Partners1.110.530.53PMDPsychemedics0.011.591.59Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCCMConcord Medical ServicesN/AOPGNOpGen2.68%PIIIP3 Health Partners7.75%PMDPsychemedics32.07%Insider OwnershipCompanyInsider OwnershipCCMConcord Medical Services46.50%OPGNOpGen43.80%PIIIP3 Health Partners15.76%PMDPsychemedics13.96%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCCMConcord Medical Services9704.34 million2.32 millionNot OptionableOPGNOpGen1008.36 million4.70 millionNot OptionablePIIIP3 Health Partners5007.18 million294.74 millionNot OptionablePMDPsychemedics1406.11 million5.26 millionNot OptionablePMD, PIII, OPGN, and CCM HeadlinesRecent News About These CompaniesPsychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing InsightsMarch 3, 2025 | markets.businessinsider.comPhoenix Molecular Designs Launches Phase II Trial in RSK2-High Breast CancerFebruary 21, 2025 | precisionmedicineonline.comInsider Buying: Psychemedics Co. (NASDAQ:PMD) Major Shareholder Acquires 60,000 Shares of StockDecember 18, 2024 | insidertrades.comPsychemedics Co. (NASDAQ:PMD) Major Shareholder Purchases $19,355.07 in StockDecember 13, 2024 | insidertrades.comInsider Buying: Psychemedics Co. (NASDAQ:PMD) Director Purchases 1,409,712 Shares of StockDecember 6, 2024 | insidertrades.comPsychemedics announces reverse stock split, forward stock splitDecember 3, 2024 | markets.businessinsider.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | gurufocus.comPsychemedics Corporation Announces 1-for-5,000 Reverse Stock Split Followed by 5,000-for-1 Forward Stock SplitDecember 2, 2024 | quiverquant.comPsychemedics Corporation Announces Reverse and Forward Stock SplitDecember 2, 2024 | globenewswire.comPsychemedics reminds stockholders to cast votes for Annual MeetingNovember 19, 2024 | markets.businessinsider.comPsychemedics Corporation Reminds Stockholders to Cast Their Votes for Upcoming Annual Meeting of StockholdersNovember 18, 2024 | markets.businessinsider.comPsychemedics Reports Improved Losses Amid Revenue DipNovember 15, 2024 | markets.businessinsider.comPsychemedics Corporation Reports Third Quarter 2024 Financial ResultsNovember 12, 2024 | globenewswire.comPsychemedics Corporation (PMD)October 15, 2024 | finance.yahoo.comPsychemedics Releases First-Ever Education Insights Report: Uncovering Drug Trends in Educational Institutions Through Hair TestingSeptember 26, 2024 | globenewswire.comPsychemedics Corporation Launches New Ketamine Hair Testing ServiceAugust 29, 2024 | finance.yahoo.comPsychemedics Corporation Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comPsychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its ...August 12, 2024 | bakersfield.comPsychemedics Corporation’s Board of Directors Approves Plan to Terminate Registration of Its Common StockAugust 12, 2024 | finance.yahoo.comPsychemedics Corporation's Board of Directors Approves Plan to Terminate Registration of Its Common StockAugust 12, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePMD, PIII, OPGN, and CCM Company DescriptionsConcord Medical Services NYSE:CCM$7.64 +0.46 (+6.39%) Closing price 03:50 PM EasternExtended Trading$7.45 -0.19 (-2.43%) As of 06:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Concord Medical Services Holdings Limited, through its subsidiaries, operates a network of radiotherapy and diagnostic imaging centers in the People's Republic of China. It operates in two segments, Network and Hospital. The company's services include linear accelerators and external beam radiotherapy, proton therapy system, gamma knife radiosurgery, and diagnostic imaging services. Its other treatments and diagnostic services comprise positron emission tomography-computed tomography and magnetic resonance imaging scanners. In addition, the company provides clinical support services, such as developing treatment protocols for doctors, and organizing joint diagnosis between doctors in its network and clinical research, as well as helps to recruit and determine the compensation of doctors and other medical personnel. Further, it offers radiotherapy and diagnostic equipment leasing, management services, and premium cancer and proton treatment services to hospitals, as well as teleconsultation and medical information technology services; and sells medical equipment. Additionally, the company operates specialty cancer hospitals, which offers radiation, imaging, test laboratory, inpatient, and nursing services. Concord Medical Services Holdings Limited was founded in 1997 and is headquartered in Beijing, the People's Republic of China.OpGen NASDAQ:OPGN$4.99 +0.01 (+0.20%) As of 12:22 PM EasternOpGen, Inc., a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits. The company's products also comprise ARES Technology Platform, including ARES reference database on antimicrobial resistance using next generation sequencing technology and artificial intelligence powered bioinformatics solutions for antibiotic response prediction; and Unyvero Platform, an automated sample-to-answer molecular diagnostics platform that integrates automated sample preparation, analysis, and identification of disease relevant pathogens and antibiotic resistance markers. It also utilizes molecular diagnostics and informatics to help combat infectious diseases. The company helps clinicians with information about life threatening infections to enhance patient outcomes, and to decrease the spread of infections caused by multidrug-resistant microorganisms. OpGen, Inc. has a collaboration with the New York State Department of Health and ILÚM Health Solutions, LLC to develop a research program to detect, track, and manage antimicrobial-resistant infections at healthcare institutions. The company was incorporated in 2001 and is headquartered in Rockville, Maryland.P3 Health Partners NASDAQ:PIII$8.51 -0.12 (-1.33%) Closing price 03:58 PM EasternExtended Trading$8.55 +0.04 (+0.53%) As of 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.P3 Health Partners Inc., a patient-centered and physician-led population health management company, provides superior care services in the United States. It operates clinics and wellness centers. P3 Health Partners Inc. was founded in 2020 and is based in Henderson, Nevada.Psychemedics NASDAQ:PMDPsychemedics Corporation, together with its subsidiaries, engages in the provision of testing services for the detection of drugs of abuse and other health markers through the analysis of hair samples in the United States and internationally. It offers screening and confirmation by mass spectrometry using industry-accepted practices for cocaine, marijuana, and PCP; amphetamines, including ecstasy, eve, and Adderall; opioids, such as heroin metabolite, morphine, hydrocodone, hydromorphone, oxycodone, oxymorphone, and codeine; synthetic cannabinoids comprising K2, Spice, and Blaze; benzodiazepines consisting of Xanax, Valium, and Ativan; and nicotine, fentanyl and fentanyl analogs, and alcohol. The company's testing results provide quantitative information that could indicate the approximate amount of drug ingested, as well as historical data that could show a pattern of individual drug use over a longer period-of-time. It offers its services to employers for job applicant and employee testing; and treatment professionals, law enforcement agencies, school administrators, and parents concerned about their children's drug use. The company was incorporated in 1986 and is headquartered in Dallas, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
